AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01545349 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis for 28 days.
Study NCT01545349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine
Description: 0.2 mL pre-filled, single use intranasal spray
Study NCT01545349 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Live attenuated influenza vaccine
Description: 0.2 mL pre-filled, single use intranasal spray
Study NCT01305109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ORV 116E
Description: Oral Rotavirus Vaccine 116E (ORV 116E), 10\^5.0 FFU of Bharat Biotech International Limited, 3 doses of 0.5mL at 4 week intervals
Study NCT01305109 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 doses of 0.5 mL at 4 week intervals
Study NCT02125149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Study NCT01859637 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Zarzio®/Filgrastim HEXAL® solution for injection was provided in prefilled syringes with two strengths at 300 μg/0.5 ml (30 MU) and 480 μg/0.5 ml (48 MU). Dosage and duration for each patient is as per the recommendations in the SmPC.
Study NCT00978536 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive impairment of multiple sclerosis
Description: Patients will get a lumbar puncture in order to measure the biomarkers in the CSF, a neuropsychological exam, an evaluation of the hippocampal volume by MRI and a cerebral scintigraphy.
Study NCT02431949 — intervention group
Intervention type: OTHER
Intervention: Admission to BCPP
Description: There is no intervention associated with this study.
Study NCT03685409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride 500 MG
Description: Metformin hydrochloride tablets 500 mg given orally once daily.
Study NCT03685409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Starch Placebo oral tablets will be given once daily to the control group
Study NCT02658214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel + carboplatin
Description: IV infusion
Study NCT02658214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin + etoposide
Description: IV infusion
Study NCT02658214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine + carboplatin
Description: IV infusion
Study NCT02658214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (paclitaxel-albumin) + carboplatin
Description: IV infusion
Study NCT02658214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)
Description: IV infusion and bolus administration
Study NCT02658214 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: IV infusion
Study NCT00693381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone and prednisone
Description: IV and oral
Study NCT02238327 — intervention group
Intervention type: PROCEDURE
Intervention: Lung function testing
Description: The routine lung function endpoints of FVC, FEV1, FEV1/FVC, and FEF25-75% will be measured before and after bronchodilator administration (4 puffs of albuterol). The best of three reproducible forced expiratory attempts is used in analysis. Percent- predicted spirometric values are based on age, height, gender, and ethnicity. DLco will be measured using the automated single-breath procedure of the integrated testing system, which conforms to ATS standards. DLco will be adjusted for hemoglobin and carboxyhemoglobin.
Study NCT02238327 — intervention group
Intervention type: PROCEDURE
Intervention: Six-Minute walk test
Description: Six-minute walk tests are performed in a 100 foot (30.48 m) segment of straight hallway marked at 10 foot (3 m) intervals. In addition to the usual ATS protocol, the patient is monitored, when available, with Bluetooth wireless pulse oximetry and the time and distance recorded after six minutes and if they desaturate to \<88%. Dyspnea (Borg 0-10) and perceived exertion (Borg 6-20) scales are completed at the beginning and the end of test.
Study NCT02658214 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tremelimumab
Description: IV infusion
Study NCT02658214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (paclitaxel-albumin) + gemcitabine
Description: IV infusion
Study NCT02658214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin + 5-fluorouracil (5FU)
Description: IV infusion
Study NCT01015287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered once orally
Study NCT01015287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Administered orally
Study NCT04440150 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Appendectomy
Description: Open or Laparascopic Surgery
Study NCT04323683 — intervention group
Intervention type: GENETIC
Intervention: Microarray
Description: High throughput technique for determining global gene expression of the condition of interest
Study NCT00469885 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine replacement
Description: For reduction
Study NCT00469885 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Motivational counseling
Description: No drugs
Study NCT03531645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Neoadjuvant Treatment (Cycles 1-4): Fulvestrant 500 mg injection in buttocks on Days 1 and 15 of Cycle 1 and Day 1 of Cycles 2-4.~Adjuvant Treatment (Cycles 5 and beyond): Fulvestrant 500 mg injection in buttocks on Day 1 of each cycle.~Study cycle is 28 days.
Study NCT03531645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Neoadjuvant Treatment (Cycles 1-4): Abemaciclib 150 mg by mouth On Days 1-28 of each cycle.~Adjuvant Treatment (Cycles 5 and beyond): On Days 1-28 of each cycle, you will take Abemaciclib 150 mg by mouth on Days 1-28 of each cycle.~Study cycle is 28 days.
Study NCT04007796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Apnea and Insomnia Relief (AIR)
Description: This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. The main components of the AIR protocol are (a) psychoeducation, (b) motivational interviewing, (c) PAP adherence strategies, and (d) cognitive behavioral therapy for insomnia.
Study NCT04007796 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education (SE)
Description: This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. Topics covered include the sleep cycle, sleep across the lifespan, sleep and the mind, evening activities and the sleep environment, and daytime activities and sleep.
Study NCT00974350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SABER-Bupivacaine
Description: Injectable Extended Release Solution; 2.5 mL SABER-Bupivacaine/Once
Study NCT00974350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SABER-Bupivacaine
Description: Injectable Extended Release Solution; 5.0 mL SABER-Bupivacaine/Once
Study NCT00974350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SABER-Placebo
Description: Injectable Solution; 2.5 or 5.0 mL SABER-Placebo/Once
Study NCT03616691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Stage I: The dose level of atezolizumab proposed to be tested in this study is 1200 mg administered by IV infusion every 3 weeks (q3w)
Study NCT03616691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Stage II: Once radiologic progression confirmed from atezolizumab monotherapy (stage 1), 1200mg of atezolizumab would be administered with 15mg/kg of bevacizumab as combination therapy every 3 weeks.
Study NCT03008655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intradermal tranexamic acid
Description: intradermal tranexamic acid injection
Study NCT03008655 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nd-YAG
Description: six session at two-week interval of low influence 1064 Nd:YAG laser (6 mm spot size, energy fluence 1.2 - 1.4 J/cm 2 at 10 Hz)
Study NCT03008655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd-YAG
Description: six session at two-week interval of low influence 1064 Nd:YAG laser (6 mm spot size, energy fluence 1.2 - 1.4 J/cm 2 at 10 Hz)
Study NCT06098313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: -Cyclophosphamide 50 mg/kg/day i.v. daily on days 3 and 4 (for 2 days)
Study NCT00863330 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: Tumor harvest process tumor infiltrating lymphocytes. Non myeloblative chemotherapy consisting of cyclophosphamide and fludarabine. Infusion of TIL cells followed by high dose IL-2.
Study NCT01215760 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training with a mirror
Description: Early sensory reeducation group, started at the first week postoperatively, using specific guidelines using the mirror training and stimulation of the contralateral side. Initially, the stimulation will be unilateral and later bilateral, after the removal of the splint in 4 weeks.
Study NCT00731432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Identical in shape and texture to treatment patch
Study NCT01215760 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No mirror therapy
Description: The classical group iniciates after 16 weeks postoperatively and follow a standard home protocol for sensory reeducation without the mirror. It begins with recognition of textures and objects, and specific rehabilitation, if any associated injuries.
Study NCT00232687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Tablets, Oral, 15 mg fixed dose (week 1-5) flexible dose 10-30 mg (week 6-12), once daily, 12 weeks.
Study NCT00232687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Tablets, Oral, Uptitration: 5 mg (week 1), 10 mg (week 2 and 3), 15 mg(week 4 and 5) flexible 10-30mg from week 6-12, once daily, 12 weeks.
Study NCT01360086 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 6 cycles of intravenous Cetuximab (500mg/m²),
Study NCT01360086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatine (50mg/m²)
Study NCT01360086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: LV5FU2s (folinic acid 400mg/m², 5FU bolus 400mg/m², and continuous infusion of 5FU 2400mg/m²) every 2 weeks
Study NCT01360086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT01360086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT01360086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT01360086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study NCT01360086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Surgery was planned 3-4 weeks after the end of neaodjuvant CT
Study NCT04598763 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: smell the odors of the olfactory rehabilitation kit according to the classic or intensive method
Description: regardless of the randomization group, the patient will smell each odor for 10 seconds with a 10 second interval between odors.
Study NCT06416241 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: EYLEA 2 MG in 0.05 ML Injection
Description: Intravitreal injection
Study NCT00767481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost/Brinzolamide
Description: Eye drop suspension, once daily
Study NCT00767481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cosopt
Description: Eye drop solution, one drop BID
Study NCT04366635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Impacted third molar surgery
Description: Under local anesthesia, flap will be raised and mesioangular or horizontal impacted third molar tooth will be removed with routine technique. And then extraction socket will be irrigated with salin and will be primarily closed.
Study NCT04366635 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Impacted third molar surgery
Description: Under local anesthesia, flap will be raised and mesioangular or horizontal impacted third molar tooth will be removed with routine technique. And then extraction socket will be irrigated with salin and will be primarily closed.
Study NCT04366635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of mineralised plasmatic matrix
Description: After extraction of impacted third molar tooth, Mineralized Plasmatic Matrix will be placed to the socket as a graft material and will be covered with Platelet Rich Fibrin membrane. Then wound will be primarily closed.
Study NCT04366635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of β-tricalcium phosphate
Description: After extraction of impacted third molar tooth, β-tricalcium phosphate will be placed to the socket as a graft material and will be covered with Platelet Rich Fibrin membrane. Then wound will be primarily closed.
Study NCT02238327 — intervention group
Intervention type: RADIATION
Intervention: Quantitative CT scans
Description: Subjects will undergo a standard chest CT. The CT scans will use a phantom shipped between sites to standardize results and capture contiguous volume scans acquired at slice thicknesses of 5.0 mm in the axial plane and reconstructed with 512 x 512 pixel matrices. CT examinations will encompass the entire thorax and be performed during a breath-hold at end-inspiration. We will measure % of lung tissue below a threshold for emphysema (i.e. -950 Hounsfield units). Measurements have been histologically-verified and give reproducible measurements. The data set is assembled and analyzed with the image data anonymized.
Study NCT02238327 — intervention group
Intervention type: PROCEDURE
Intervention: Nasal secretion and cell collection
Description: Participants will be instructed to blow their nose to remove accumulated mucus. Two sprays of commercially available nasal saline will be instilled in each nostril. The participant will then be ask to exhale through the rinsed nostril into a specimen cup. We will repeat this up to 5 times on each side depending on the participants' tolerance to the procedure. Using an otoscope, a small curette will then be used to collect 3 to 5 samples of nasal cells from each nostril. These samples will be used immediately for analysis or banked for future study.
Study NCT02238327 — intervention group
Intervention type: PROCEDURE
Intervention: Echocardiogram
Description: The cardiac ultrasound will use standard ultrasound techniques to image two-dimensional slices of the heart using 3D real-time imaging.
Study NCT02950974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sterofundin
Description: Fluid loading
Study NCT02950974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sterofundin
Description: Fluid loading
Study NCT02950974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSS
Description: Fluid loading
Study NCT02950974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSS
Description: Fluid loading
Study NCT03608007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-396 Capsule
Description: 225 mg once daily
Study NCT00866775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Description: 1600 mg QD
Study NCT00866775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Description: 1200 mg QD
Study NCT00714363 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LASIK
Description: Refractive surgery
Study NCT00714363 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SBK
Description: Refractive surgery
Study NCT01887301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sativex
Description: Patients receive four sprays (each 100 uL) of Sativex to the oral mucosa, which contain 10.8 mg THC and 10 mg CBD in total.
Study NCT01887301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Patients receive four sprays (each 100 uL) of Sativex to the oral mucosa, which contain 10.8 mg THC and 10 mg CBD in total.
Study NCT03878186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care (UC)
Description: Usual Care: single in-person psycho-educative session with information about HIV, transmission, natural history of the disease, importance of antiretroviral adherence. All the information is based on guidelines and information sheets from InfoVIHt
Study NCT03878186 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care (UC)
Description: Usual Care: single in-person psycho-educative session with information about HIV, transmission, natural history of the disease, importance of antiretroviral adherence. All the information is based on guidelines and information sheets from InfoVIHt
Study NCT03878186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Cognitive behavioral therapy (CBT): Usual Care + Cognitive-behavioral therapy program intervention (AppraHIV). This intervention involves 7 in-person weekly sessions based on Adjuvant Psychological Therapy centered in three areas: cognitive appraisal, affect and adherence and self-care, everyone with different techniques: cognitive techniques, diaphragmatic breathing, scheduling pleasurable activities, use of pillbox, solving problems, planning for the future, etc. The intervention was manualized (according to Template for Intervention Description and Replication TIDieR), piloted and validated.
Study NCT02577835 — intervention group
Intervention type: DEVICE
Intervention: Ambulatory blood pressure monitoring
Description: Ambulatory blood pressure monitoring with arterial stiffness evaluation at 6-12 month intervals.
Study NCT03483818 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Assessment & Treatment of HCV infection with oral antivirals
Description: This is a cluster randomised trial of directly observed anti HCV therapy versus conventional care in HCV positive patients, who are in a pharmacist delivered OST program, where the patients attending an individual pharmacist are the cluster. Pharmacies participating in the trial will be allocated to conventional care pathway or the pharmacist-led pathway.
Study NCT03210038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Pad soaked with lidocaine gel (Esracaine) left on the introitus for 5 minutes
Study NCT03210038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Water based non-anesthetic lubricant gel left on the introitus for 5 minutes.
Study NCT01793584 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic hysterectomy
Description: LAVH, TLH
Study NCT01793584 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal hysterectomy
Description: TAH
Study NCT00072514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00072514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00072514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO
Study NCT00072514 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV in CD20-POSITIVE LYMPHOMAS cases
Study NCT00470379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: resiquimod
Description: Escalating the dose of resiquimod applied to a fixed area of skin followed by application of topical NY-ESO-1b.
Study NCT03574805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRS-060
Description: Study drug
Study NCT03574805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalant designed to mimic PRS-060
Study NCT01239303 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Citrulline
Description: single dose
Study NCT01239303 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: alanine
Description: single dose
Study NCT04524429 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: Bariatric surgery includes sleeve gastrectomy and gastric bypass.
Study NCT01594814 — intervention group
Intervention type: PROCEDURE
Intervention: RFA
Description: radiofrequency ablation of slow pathway or accesory pathway
Study NCT02773537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve catheter and sciatic nerve block
Description: This nerve block is believed to cause both muscle weakness and numbness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it. This technique causes both the front and the back of the knee to be numb.